You are here

Maraviroc in Rheumatoid Arthritis

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Huntington Beach, California, 92646 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Must be legal age of consent

- Must have active rheumatoid arthritis based upon the American College of Rheumatology
(ACR) 1987 (Revised Criteria); minimum disease criteria required for entry into the
efficacy component of the study

- Must meet ACR 1991 Revised Criteria for Global Functional Status in RA, Class I, II,
or III

- Must be receiving methotrexate for at least 12 weeks duration and on a stable dose for
4 weeks.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Diagnosed with any other inflammatory arthritis or a secondary non-inflammatory
arthritis that would interfere with disease activity assessments.

- Subject receiving prior treatment with certain medications for rheumatoid arthritis

- Tuberculosis and/or a positive tuberculin reaction

- Significant trauma or major surgery within 2 months

- History of alcohol and/or drug abuse outside of a defined period of abstinence

- History of or a finding at screening of postural hypotension

- Any condition that would affect the oral absorption of the drug

- History of cancer and in remission less than 3 years or Grade III-IV congestive heart
failure

- Having an infection of human immunodeficiency virus (HIV), Hepatitis B or C or
evidence of any active infection

- Abnormalities of clinical or laboratory assessments completed at the screening visit
such as elevated liver enzymes, decreased hemoglobin or an abnormal ECG

- Having a positive chemokine receptor 5 (CCR5) delta 32 mutation

- Requiring the use of certain medications

- Lactating or pregnant women or subjects have reproductive potential unwilling to use
an adequate method of birth control

- Chronic or recent serious or life-threatening infection; severe , progressive and/or
uncontrollable renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary,
cardiac, neurological disease within 12 weeks of the first dose.

NCT00427934
Pfizer
Terminated
Maraviroc in Rheumatoid Arthritis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Rheumatoid Arthritis
NCT03992781
All Genders
Rheumatoid Arthritis
NCT03981900
All Genders
18+
Years
Multiple Sites
Crohn Desease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
NCT02925338
All Genders
6+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now